Raloxifene: A selective estrogen receptor modulator for the prevention of osteoporosis

Journal of Pharmacy Technology

Volumn 15, Issue 2, 1999, Pages 37-45

  Hagmeyer, Kathleen O ^a   Meyer, Tamara K ^b  

^a UNIVERSITY OF TOLEDO   (United States)

^b Rite Aid Pharmacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN RECEPTOR; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; RALOXIFENE;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HORMONE RECEPTOR INTERACTION; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; MASTALGIA; META ANALYSIS; OSTEOPOROSIS; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINITIS;

EID: 0032965007     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512259901500203     Document Type: Article

References (45)

1. Kanis JA, Devogelaer JP, Gennari C. Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European Foundation for Osteoporosis and Bone Disease. Osteoporosis Int 1996;6:256-61.
2. Lindsay R. Osteoporosis: a guide to diagnosis, prevention and treatment. New York: Raven Press, 1992:1-39.
3. Booher DL. Estrogen supplements in menopause. Cleve Clin J Med 1990;57:154-60.
4. Ray NF, Chan JK, Thamer M, Meton LJ III. Medical expenditure for the treatment of osteoporotic fractures in the United States in 1995: a report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:24-35.
5. Cummings SR, Rubin SM. The future of hip fractures in the United States: numbers, costs, and effects of postmenopausal estrogen. Clin Orthop 1990;252:63-6.
6. Krane SM, Holick MF. Metabolic bone disease. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill, 1994:2172-83.
7. Riggs BL, Melton LJ. Involutional Osteoporosis. N Engl J Med 1986; 314:1676-86.
8. Scheiber LB, Torregrosa L. Evaluation and treatment of postmenopausal osteoporosis. Semin Arthritis Rheum 1998;27:245-61.
9. Gibaldi M. Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy? J Clin Pharmacol 1997;37:1087-99.
10. Uitterlinden AG, Burger H, Huang Q, Yue F, McGuigan F, Grant S, et al. Relation of alleles of the collagen type Iα1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl J Med 1998;338:1016-21.
11. Lindsay R. Osteoporosis: a clinical overview of the diagnosis and therapy. J Musculoskel Med 1993;10:31-41.
12. Netelvitz M Estrogen therapy and osteoporosis: principles and practice. Am J Med Sci 1997;313:2-12.
13. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305-11.
14. Horowitz MC. Cytokines and estrogen in bone: anti-osteoporotic effects Science 1993;260:626-7.
15. Genant HK, Baylink DJ, Gallagher JC. Estrogens in the prevention of osteoporosis in postmenopausal women. Am J Obstet Gynecol 1989;161:1842-6
16. Gambrel RD. The true impact of HRT in menopause. Intern Med 1996,17:37-53.
17. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;276:1389-96.
18. Grady D, Rubin SM, Petitti DB, Fox ES, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
19. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med 1991;325:756-62.
20. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
21. Beresford SAA, Weiss NS, Voight LF, McKnight B. Risk of endometrial cancer in relation to use of estrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349: 458-61.
22. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA 1997;277:243-7.
23. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9.
24. Jordan CV. Biochemical pharmacology of antiestrogen action. Pharmacol Rev 1984;36:245-72.
25. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators Horm Res 1997;48:155-63.
26. Baker VL, Jaffe RB. Clinical uses of antiestrogens. Obstet Gynecol Surv 1996;51:45-9.
27. Gradishar WJ, Jordan CV. Clinical potential of new antiestrogens. J Clin Oncol 1997;15:840-52.
28. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 1983;32:1031-6.
29. Draper MW, Flowers DE, Neild JA, Huster WJ, Zerbe RL. Antiestrogenic properties of raloxifene. Pharmacology 1995;50:209-17.
30. Bryant HU, Glasebrook AL, Yang NN, Sato M. A pharmacological review of raloxifene. J Bone Miner Metab 1996;14:1-9.
31. Sato M, Glasebrook A, Bryant HU. Raloxifene: a selective estrogen receptor modulator. J Bone Miner Metab 1994;12(suppl):S9-20.
32. Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 1983;32: 2869-75.
33. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.
34. Evans G, Bryant H, Sato M, Turner RT. Raloxifene is a tissue specific estrogen agonist (abstract). Calcif Tissue Int 1994;54:339.
35. Baker VL, Draper M, Paul S, Allerheiligen S, Glant M, Shifren J, et al. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab 1998;83:6-13.
36. Prescribing information. Evista (raloxifene hydrochloride). Indianapolis: Eli Lilly and Company, 1997.
37. Heaney RP, Draper MW. Raloxifene and estrogen: comparative bone remodeling kinetics. J Clin Endocrinol Metab 1997;82:3425-9.
38. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy post-menopausal women. J Bone Miner Res 1996;11:835-42.
39. Stevenson JC. Are changes in lipoproteins during HRT important? Br J Obstet Gynaecol 1996;103(suppl 13):39-44.
40. Westerveld HT, Koch LAW, van Rijn JM, Erkelens DW, de Bruin TWA. 17 Beta-estradiol improves postprandial lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1995;80:249-53.
41. Crook D, Cust MP, Gangar KF, Worthington M, Hillard TC, Stevenson JC, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992;166:950-5.
42. Budzar AU, Marcus C, Hohnes F, Hug V, Hortobagyi G. Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 1988; 45:344-5.
43. Jordan VC, Glusman JE, Eckert S, Lippman M, Powles T, Costa A, et al. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter, double-blind, randomized trials in ≈12,000 postmenopausal women (abstract). Program and Proceedings of the 34th Annual Meeting, American Society of Clinical Oncology, Los Angeles, CA, May 19, 1998.
44. Cummings SR, Norton L, Eckert S, Grady D, Cauley J, Knickerbocker R, et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) Trial (abstract). Program and Proceedings of the 34th Annual Meeting, American Society of Clinical Oncology, Los Angeles, CA, May 19, 1998.
45. 1998 Drug topics red book. Montvale, NJ: Medical Economics Co., 1998:308,319,494,507.